Trial Profile

A study BNC210 for treatment for PTSD

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 12 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Dec 2024 According to a Bionomics media release, company is planning to initiate this Phase 3 trial in the second half of 2025.
07 Oct 2024 According to a Bionomics media release, the company have begun trial initiation activities, and on track to commence the Phase 3trial in PTSD in the second half of 2025 or sooner, contingent upon successful financing.
30 Jul 2024 According to a Bionomics media release, company announced that it will provide a corporate update and discuss the outcomes of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration regarding the advancement of BNC210 for the treatment of post-traumatic stress disorder (PTSD) into Phase 3.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com